Heidelberg Pharma
| Heidelberg Pharma
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | DE000A11QVV0 |
| founding | 1997 (Munich) |
| Seat |
Ladenburg , Germany
|
| management | Jan Schmidt-Brand (Board Spokesman) |
| Number of employees | 75 (2019) |
| sales | 7.3 million euros (2019) |
| Branch | biotechnology |
| Website | heidelberg-pharma.com |
| As of December 31, 2019 | |
The Heidelberg Pharma AG is a biotechnology -Unternehmen based in Ladenburg. It is listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard.
The company was founded in September 1997 under the name Wilex Biotechnology GmbH by a team of doctors and cancer researchers from the Technical University of Munich. With 124 iodine - Girentuximab ( Redectane ), Heidelberg Pharma AG currently has a drug candidate for tumor diagnostics in a phase III registration study . The phase III study with Girentuximab ( Rencarex ) was terminated in October 2012 because the primary endpoint of the study was not met. There was no improvement in median disease-free survival after treatment with Rencarex compared to the placebo group . The company's share then fell sharply and was at times below EUR 1. Another candidate, Upamostat ( Mesupron ), is in a Phase II program in two indications. The MEK inhibitor WX-554, acquired from UCB as part of a strategic partnership, is currently in the clinical phase I study.
In 2000, the name of Wilex Biotechnology GmbH was changed to Wilex AG. At the end of 2010, Wilex AG acquired Oncogene Science, a commercial business unit of Siemens Healthcare Diagnostics Inc., and founded Wilex Inc. as a 100% US subsidiary of Wilex AG.
As part of the m4 top cluster initiative , the then Wilex AG received in February 2012 the commitment of 2.6 million euros BMBF funding for the preclinical and clinical development of WX-037.
At the Extraordinary General Meeting 2010, the takeover of Heidelberg Pharma AG announced in November against a capital increase in kind was approved. The Ladenburg- based company developed antibody-drug conjugates (ADC) and operated as a contract research institute (CRO). After the takeover was completed, the company was converted into a GmbH . At the general meeting of Wilex AG in July 2017, it was decided to relocate the headquarters from Munich to Ladenburg and to rename Wilex AG to Heidelberg Pharma AG. The old subsidiary Heidelberg Pharma GmbH operates today under the name Heidelberg Pharma Research GmbH.
The German entrepreneur Dietmar Hopp directly and indirectly holds 75% of the company's shares.
Web links
Individual evidence
- ↑ a b key figures. In: heidelberg-pharma.com. Retrieved August 10, 2020 .
- ↑ Serious setback for the biotech company Wilex. ( Memento from October 19, 2012 in the Internet Archive ) In: Financial Times Deutschland from October 17, 2012
- ↑ WilexAG: WILEX acquires all Oncogene Science assets from Siemens Healthcare Diagnostics. (PDF; 54 kB) November 17, 2010, accessed on January 18, 2011 .
- ↑ WilexAG: press release. (PDF; 142 kB) February 6, 2012, accessed June 24, 2012 .
- ↑ WilexAG: Voting results of the extraordinary general meeting on December 15, 2010. (PDF; 23 kB) December 15, 2010, accessed on January 18, 2011 .
- ↑ Heidelberg Pharma AG: Company overview. Retrieved April 3, 2018 .
- ↑ Heidelberg Pharma AG: share price, shareholder structure, basic data. Retrieved April 3, 2018 .